These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 24815307

  • 21. Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil.
    Silveira CA, Daldegan MB, Ferrari I.
    Genet Mol Res; 2011 Sep 15; 10(3):2038-48. PubMed ID: 21968620
    [Abstract] [Full Text] [Related]

  • 22. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
    Jabbour EJ, Cortes JE, Kantarjian HM.
    Expert Rev Anticancer Ther; 2013 Dec 15; 13(12):1433-52. PubMed ID: 24236822
    [Abstract] [Full Text] [Related]

  • 23. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.
    Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M.
    Pediatr Blood Cancer; 2014 Feb 15; 61(2):355-7. PubMed ID: 24106110
    [Abstract] [Full Text] [Related]

  • 24. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D.
    Am J Hematol; 2012 Jul 15; 87(7):687-91. PubMed ID: 22473898
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
    Soysal T, Eskazan AE, Ar MC.
    Expert Rev Hematol; 2014 Dec 15; 7(6):697-9. PubMed ID: 25292262
    [Abstract] [Full Text] [Related]

  • 27. Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma.
    Ramanujam D, McNicholl F, Furby D, Richardson D, Cuthbert RJ, McMullin MF.
    Leuk Lymphoma; 2009 Oct 15; 50(10):1721-2. PubMed ID: 19757309
    [No Abstract] [Full Text] [Related]

  • 28. Generic imatinib: the real-deal or just a deal?
    Mathews V.
    Leuk Lymphoma; 2014 Dec 15; 55(12):2678-80. PubMed ID: 24798742
    [No Abstract] [Full Text] [Related]

  • 29. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.
    Yadav U, Solanki SL, Yadav R.
    J Cancer Res Ther; 2013 Dec 15; 9(3):484-6. PubMed ID: 24125987
    [Abstract] [Full Text] [Related]

  • 30. [Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 4. Diagnosis and treatment of chronic myeloid leukemia].
    Kimura S.
    Nihon Naika Gakkai Zasshi; 2013 Jul 10; 102(7):1712-9. PubMed ID: 23947233
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L.
    Vnitr Lek; 2004 Jan 10; 50(1):10-2. PubMed ID: 15015223
    [No Abstract] [Full Text] [Related]

  • 33. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB.
    J Assoc Physicians India; 2007 Feb 10; 55():99-100. PubMed ID: 17571737
    [No Abstract] [Full Text] [Related]

  • 34. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
    Saavedra D, Vizcarra F.
    Leuk Lymphoma; 2014 Dec 10; 55(12):2813-6. PubMed ID: 24724785
    [Abstract] [Full Text] [Related]

  • 35. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.
    Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, Kim DW.
    Int J Hematol; 2012 Jul 10; 96(1):47-57. PubMed ID: 22610512
    [Abstract] [Full Text] [Related]

  • 36. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
    Hamza I, Gaies E, Kastalli S, Daghfous R, El Aidli S.
    Therapie; 2014 Jul 10; 69(3):245-7. PubMed ID: 24934821
    [Abstract] [Full Text] [Related]

  • 37. Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
    Roy L, Tomowiak C, Guilhot F.
    Blood; 2011 Nov 10; 118(19):5096-8. PubMed ID: 21876122
    [No Abstract] [Full Text] [Related]

  • 38. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Inokura K, Onishi Y, Shimosegawa K, Okitsu Y, Katsuoka Y, Fujiwara T, Fukuhara N, Ishizawa K, Harigae H.
    Ann Hematol; 2012 Nov 10; 91(11):1825-6. PubMed ID: 22543830
    [No Abstract] [Full Text] [Related]

  • 39. Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
    DeAngelo DJ, Ritz J.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 1):1-3. PubMed ID: 14734443
    [No Abstract] [Full Text] [Related]

  • 40. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
    Assouline S, Laneuville P, Gambacorti-Passerini C.
    N Engl J Med; 2006 Jun 15; 354(24):2623-4. PubMed ID: 16775249
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.